UNIFIED ACCELERATION PLATFORM™ (UAP):

Alzheimer’s disease, obesity, coronary artery diseases, and stroke are not isolated, but they are deeply interconnected pathophysiological states that share overlapping etiologies, progression patterns, and therapeutic responses.

Biomed has developed Unified Acceleration Platform™, which is based on Dr. Lloyd Tran’s Unified Theory on Neurodegenerative Diseases, Metabolic Disorders, and Cardiovascular Diseases.

The Unified Theory posits that shared molecular, cellular, and systemic dysfunctions—especially in energy metabolism, chronic inflammation, and cellular senescence, neurogenesis —are central drivers of these diseases.

The Unified Acceleration Platform™ reconceptualizes neurodegenerative, metabolic, and cardiovascular diseases as interconnected manifestations of systemic dysfunction, rather than as isolated, organ-specific pathologies.

Drawing upon insights from molecular biology, epidemiology, clinical research, and systems medicine, Biomed Industries has identified common underlying mechanisms—including disrupted energy metabolism, chronic inflammation, mitochondrial dysfunction, and cellular senescence—as the shared pathophysiological basis for these conditions.

Rather than targeting symptoms within individual organs, the Platform embraces the paradigm that chronic diseases stem from system-wide dysregulation. This insight guides the rapid development of therapeutics that modulate upstream biological processes, accelerating translational research and drug development beyond traditional disease silos.

Biomed has developed a family of patented drugs for the treatment of ALS, Alzheimer’s disease, major depressive disorder, stroke, diabetes obesity, MASH and rare diseases including Rett Syndrome and Fragile X.

PRODUCTS CATEGORIES

PIPELINE